CDK4 and Miyoshi myopathy: In doing so, we highlight current gaps in our knowledge regarding MM progression, and propose important future research directions, includes studying the genetic evolution trajectory of MM from benign precursor lesions and evaluating new targeting strategies specifically for MM, such as targeting CDK4, SF3B1 or PARP, either as single agent or in combinations with ICBs.